First Time Loading...
R

R&G PharmaStudies Co Ltd
SZSE:301333

Watchlist Manager
R&G PharmaStudies Co Ltd
SZSE:301333
Watchlist
Price: 48.38 CNY -0.88%
Updated: May 2, 2024
Section:
 

Wall Street
Price Targets

Price Targets Summary
R&G PharmaStudies Co Ltd

Wall Street analysts forecast R&G PharmaStudies Co Ltd stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for R&G PharmaStudies Co Ltd is 85.07 CNY with a low forecast of 84.23 CNY and a high forecast of 87.57 CNY.

Lowest Forecast
Wall Street Target
84.23 CNY
74% Upside
Average Forecast
Wall Street Target
85.07 CNY
76% Upside
Highest Forecast
Wall Street Target
87.57 CNY
81% Upside
Lowest
Price Target
84.23 CNY
74% Upside
Average
Price Target
85.07 CNY
76% Upside
Highest
Price Target
87.57 CNY
81% Upside
R&G PharmaStudies Co Ltd Competitors:
Price Targets
LAB
Standard BioTools Inc
44% Upside
300404
Boji Medical Technology Co Ltd
553% Upside
B
086040
Biotoxtech Co Ltd
168% Upside
ICLR
ICON PLC
19% Upside
LAB
Standard BioTools Inc
44% Upside
300404
Boji Medical Technology Co Ltd
553% Upside
B
086040
Biotoxtech Co Ltd
168% Upside
ICLR
ICON PLC
19% Upside
688621
Beijing Sun-Novo Pharmaceutical Research Co Ltd
33% Upside
W
2268
WuXi XDC Cayman Inc
42% Upside
STVN
Stevanato Group SpA
24% Upside
MEDP
Medpace Holdings Inc
8% Upside

Revenue
Forecast

Revenue Estimate
R&G PharmaStudies Co Ltd

For the last 2 years the compound annual growth rate for R&G PharmaStudies Co Ltd's revenue is 15%. The projected CAGR for the next 3 years is 24%.

15%
Past Growth
24%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
R&G PharmaStudies Co Ltd

For the last 2 years the compound annual growth rate for R&G PharmaStudies Co Ltd's operating income is 5%. The projected CAGR for the next 3 years is 41%.

5%
Past Growth
41%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
R&G PharmaStudies Co Ltd

For the last 2 years the compound annual growth rate for R&G PharmaStudies Co Ltd's net income is 16%. The projected CAGR for the next 3 years is 33%.

16%
Past Growth
33%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is R&G PharmaStudies Co Ltd's stock price target?
Price Target
85.07 CNY

According to Wall Street analysts, the average 1-year price target for R&G PharmaStudies Co Ltd is 85.07 CNY with a low forecast of 84.23 CNY and a high forecast of 87.57 CNY.

What is R&G PharmaStudies Co Ltd's Revenue forecast?
Projected CAGR
24%

For the last 2 years the compound annual growth rate for R&G PharmaStudies Co Ltd's revenue is 15%. The projected CAGR for the next 3 years is 24%.

What is R&G PharmaStudies Co Ltd's Operating Income forecast?
Projected CAGR
41%

For the last 2 years the compound annual growth rate for R&G PharmaStudies Co Ltd's operating income is 5%. The projected CAGR for the next 3 years is 41%.

What is R&G PharmaStudies Co Ltd's Net Income forecast?
Projected CAGR
33%

For the last 2 years the compound annual growth rate for R&G PharmaStudies Co Ltd's net income is 16%. The projected CAGR for the next 3 years is 33%.

ALPHA SPREAD
Join more than 133,300+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.